Hutchison China Meditech Ltd diskutieren
Hutchison China Meditech Ltd
WKN: A2PJ5B / Name: Chi-Med / Aktie / Pharmazeutika / Mid Cap /
Pharma SecteurProduits
HCM offers investors a strong pipeline of differentiated candidates
The stock offers investors a strong pipeline (up to 15 possible Breakthrough Therapy Designations), China exposur, validating partnerships and several upcoming catalysts. Downside appears limited due to having several irons in the fire, low cash burn as a result of its prescription drug commercial services segment offsetting clinical costs and quite a few pivotal readouts lined up over the next couple years.
stratec stimmt am 19.02.2018 dem Buy-Gesamtsentiment mit dem Kursziel 5990.0p zu.
Neueste Beiträge
aliacacia in Porsche Automobil Holding SE diskutieren